Literature DB >> 21946214

Low molecular weight heparin downregulates tissue factor expression and activity by modulating growth factor receptor-mediated induction of nuclear factor-κB.

Camille Ettelaie1, Donna Fountain, Mary Elizabeth W Collier, Azza M Elkeeb, Yu Pei Xiao, Anthony Maraveyas.   

Abstract

Treatment of cancer patients with low molecular weight heparin (LMWH) appears to have beneficial effects. In this study, the influence of low molecular weight heparin (LMWH) on tissue factor (TF) expression and activity in five cell lines from various tissues was analysed and explored. Incubation of cells with LMWH (0-2000μg/ml) resulted in the downregulation of TF mRNA expression which was both LMWH concentration-dependent and time-dependent. Downregulation of TF was also measured as decreased cellular TF antigen and activity. Consistently, incubation of cells with LMWH suppressed the nuclear localisation and the transcriptional activity of NFκB. Decreased TF mRNA was largely achievable by incubating the cells with an NFκB inhibitor alone whilst incubation with betulinic acid to activate NFκB reversed the inhibitory influence of LMWH. Cells were also incubated with a range of concentrations of EGF (0-10ng/ml), bFGF (0-20ng/ml) or VEGF (0-4ng/ml) in the presence or absence of LMWH (200μg/ml) for 24h and TF antigen measured. Inclusion of LMWH reduced TF expression in response to EGF, bFGF or VEGF but TF expression was partially restored by increasing concentrations of the growth factors. We conclude that LMWH downregulates TF expression in vitro through a mechanism that involves interference with the function of growth factors which in turn is mediated through the downregulation of the transcriptional activity of NFκB. This mechanism may also explain some of the beneficial influences attributed to LMWH therapy in the treatment of cancer patients. Copyright Â
© 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21946214     DOI: 10.1016/j.bbadis.2011.09.007

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  13 in total

Review 1.  The intertwined fates of inflammation and coagulation in glioma.

Authors:  Angela Cho; Kelly J McKelvey; Adrian Lee; Amanda L Hudson
Journal:  Mamm Genome       Date:  2018-07-30       Impact factor: 2.957

2.  Extrahepatic Portal Venous Obstruction With Hepatic Enzyme Elevation Resembling Hepatitis in Patients With Cancer.

Authors:  Tzu-Yao Liao; Chuang-Chi Liaw; Hui-Ching Hsu; Chia-Hsun Hsieh; John Wen-Cheng Chang; Yu-Hsiang Juan
Journal:  In Vivo       Date:  2019 Sep-Oct       Impact factor: 2.155

3.  Heparin Decreases in Tumor Necrosis Factor α (TNFα)-induced Endothelial Stress Responses Require Transmembrane Protein 184A and Induction of Dual Specificity Phosphatase 1.

Authors:  Sara Lynn N Farwell; Daniela Kanyi; Marianne Hamel; Joshua B Slee; Elizabeth A Miller; Mark D Cipolle; Linda J Lowe-Krentz
Journal:  J Biol Chem       Date:  2016-01-14       Impact factor: 5.157

4.  The Role of Pulmonary Veins in Cancer Progression from a Computed Tomography Viewpoint.

Authors:  Chuang-Chi Liaw; Hung Chang; Tzu-Yao Liao; Ming-Sheng Wen; Chih-Teng Yu; Yu-Hsiang Juan
Journal:  J Oncol       Date:  2016-09-22       Impact factor: 4.375

5.  Low molecular weight heparin and direct oral anticoagulants influence tumour formation, growth, invasion and vascularisation by separate mechanisms.

Authors:  Sophie Featherby; Yu Pei Xiao; Camille Ettelaie; Leonid L Nikitenko; John Greenman; Anthony Maraveyas
Journal:  Sci Rep       Date:  2019-04-18       Impact factor: 4.379

6.  Clinical Protocol to Prevent Thrombogenic Effect of Liver-Derived Mesenchymal Cells for Cell-Based Therapies.

Authors:  Louise Coppin; Mustapha Najimi; Julie Bodart; Marie-Sophie Rouchon; Patrick van der Smissen; Stéphane Eeckhoudt; Géraldine Dahlqvist; Diego Castanares-Zapatero; Mina Komuta; Sanne L Brouns; Constance C Baaten; Johan W M Heemskerk; Sandrine Horman; Nathalie Belmonte; Etienne Sokal; Xavier Stéphenne
Journal:  Cells       Date:  2019-08-07       Impact factor: 6.600

Review 7.  Thrombogenic Risk Induced by Intravascular Mesenchymal Stem Cell Therapy: Current Status and Future Perspectives.

Authors:  Louise Coppin; Etienne Sokal; Xavier Stéphenne
Journal:  Cells       Date:  2019-09-27       Impact factor: 6.600

8.  Fibroblast growth factor receptor 3 interacts with and activates TGFβ-activated kinase 1 tyrosine phosphorylation and NFκB signaling in multiple myeloma and bladder cancer.

Authors:  Lisa Salazar; Tamara Kashiwada; Pavel Krejci; April N Meyer; Malcolm Casale; Matthew Hallowell; William R Wilcox; Daniel J Donoghue; Leslie Michels Thompson
Journal:  PLoS One       Date:  2014-01-23       Impact factor: 3.240

9.  Characterization of physical properties of tissue factor-containing microvesicles and a comparison of ultracentrifuge-based recovery procedures.

Authors:  Camille Ettelaie; Mary E W Collier; Anthony Maraveyas; Rammile Ettelaie
Journal:  J Extracell Vesicles       Date:  2014-08-13

10.  Analysis of the potential of cancer cell lines to release tissue factor-containing microvesicles: correlation with tissue factor and PAR2 expression.

Authors:  Camille Ettelaie; Mary Ew Collier; Sophie Featherby; Naima E Benelhaj; John Greenman; Anthony Maraveyas
Journal:  Thromb J       Date:  2016-01-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.